REG - Renalytix PLC - Directorate Change

RenalytixAnnouncement

05/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241105:nRSE8981Ka&default-theme=true

RNS Number : 8981K  Renalytix PLC  05 November 2024

 

Renalytix plc

("Renalytix" or the "Company")

 

Directorate Change

Julian Baines MBE appointed as Executive Chairman

 

LONDON and NEW YORK, 5 November 2024 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), an artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to drive improved
patient outcomes and advance value-based care, announces the appointment of
Julian Baines MBE as Executive Chairman after shareholders approved the
resolution passed at the Company's General Meeting on 31 October 2024. Julian
replaces Christopher Mills who will move to a Non-Executive Director role.

 

Julian has significant experience in the life science industry and was the CEO
of EKF Diagnostics Holdings Plc ("EKF") and BBI Holdings plc. Julian rejoined
the executive team at EKF as Executive Chairman in February 2023. Julian is
also currently Non-Executive Chairman of Verici Dx plc. Before joining EKF, he
undertook a management buyout at BBI in 2000, a flotation on AIM in 2004 and
was responsible for selling the business to Alere Inc. (now part of Abbott
Laboratories) in 2008 for c. £85 million. Julian was previously Non-Executive
Chairman of Renalytix from March 2018 to June 2020.

Julian Baines MBE

Executive Chairman of Renalytix PLC

 

James McCullough, CEO of Renalytix plc, commented: "I am delighted to welcome
Julian back to the Board of Renalytix. Julian has a wealth of knowledge in the
sector and significant experience with AIM listed healthcare companies which
will be paramount toward supporting the commercial success of our business.
Most importantly, I would like to thank Christopher for his continuing
contribution to Renalytix. It is a pleasure to work alongside him, and his
leadership as Chairman has been invaluable."

 

Additional Disclosures Required under the AIM Rules for Companies

Julian Huw Baines (aged 60) has held the following directorship or
partnerships in the past five years:

 

 Current directorships/partnerships  Previous directorships/partnerships (last five years)
 Verici Dx PLC                       Intuitive Investments Group PLC
 EKF Diagnostics Holdings PLC        Trellus Health PLC
 J & K (Cardiff) Limited             EKF Molecular Diagnostics Limited
                                     Quotient Diagnostics Limited
                                     360 Genomics Limited
                                     EKF Diagnostics Limited
                                     Renalytix PLC

 

Julian Baines was a director of BB Electronics Limited, which went into
liquidation in 1991 with a creditor shortfall of approximately £400,000. He
was also a director of Calibre Communications Limited, which went into
liquidation in 1991 with a creditor shortfall of approximately £20,000.
Julian Baines was not the subject of public criticism by the liquidator in
connection with the liquidations.

 

Julian Baines and persons closely associated (as defined under MAR) with Mr
Baines currently hold 1,801,711 ordinary shares of £0.0025 each in the
Company.

 

Save as disclosed above, there is no further information to be disclosed in
respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph
(g) of the AIM Rules for Companies.

 

For further information, please contact:

 

 Renalytix plc                                www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                        Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)  Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker)                Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                          Tel: 020 7933 8780 or renalytix@walbrookpr.com
                                              (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings                Mob: 07980 541 893 / 07407 804 654

 CapComm Partners
 Peter DeNardo                                Tel: 415-389-6400 or investors@renalytix.com (mailto:investors@renalytix.com)

 

About Renalytix

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(http://www.renalytix.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUSOARSOUARUA